Third Bridge Forum’s CRO Week: analysis of key market players

The outsourced pharma market could be worth USD 100bn by 2028 despite a slowdown in biotech funding, industry specialists have told Third Bridge Forum. We recently dived into the world of contract research organisations (CROs), hosting five expert Interviews on the key players, their competitive dynamics, and broader clinical research advancements. We closely examined the impact of the biotech funding slowdown, leading to a prioritisation of capital allocation after Covid-related headwinds.